Polymorphs of valsartan

Details Polymorphs of valsartan Polymorphs of valsartan

2006-09-12

2006-09-12

Saeed, Kamal A. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C548S253000

Reexamination Certificate

active

07105557

ABSTRACT:
Provided are crystalline and amorphous form of valsartan, and processes for their preparation.

REFERENCES:
patent: 5260325 (1993-11-01), Markwalder et al.
patent: 5399578 (1995-03-01), Buhlmayer et al.
patent: 5965592 (1999-10-01), Buhlmayer et al.
patent: 6271375 (2001-08-01), Villa et al.
patent: 6294197 (2001-09-01), Wagner et al.
patent: 6395728 (2002-05-01), Webb et al.
patent: 6465502 (2002-10-01), Bullock et al.
patent: 6485745 (2002-11-01), Wagner et al.
patent: 0 443 983 (1991-08-01), None
patent: WO97/30036 (1997-08-01), None
patent: WO99/67231 (1999-12-01), None
patent: WO 01/82858 (2001-11-01), None
patent: WO 02/06253 (2002-01-01), None
patent: WO 03/070246 (2003-08-01), None
patent: WO 03/089417 (2003-10-01), None
patent: WO 04/026847 (2004-04-01), None
Peter Buhlmayer, et al., Bioorgan. & Med. Chem. Let., 4(1) 29-34 (1994).
Th. Moenius, et al., J. Labelled Cpd. Radiopharm., 43(13) 1245-1252 (2000).
Borka L., et al., “Crystal Polymorphism of Pharmaceuticals”,Acta Pharm. Jugosl., 40, (1990) 71-94.
Merck Index (12thedition, p. 1691, Valsartan n. 10051).
Qingzhong Jia, et al., Zhongguo Yiyao Gongye Zazhi, 32(9) 385-387 (2001).

Affiliated with

Also associated with

Rating

Polymorphs of valsartan does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Polymorphs of valsartan, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Polymorphs of valsartan will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3606824